Drug interactions
Elvitegravir / cobicistat / emtricitabine / tenofovir df + Regorafenib
Severity: Major
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Regorafenib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Cobicistat is a strong CYP3A4 inhibitor and may increase regorafenib concentrations while reducing its active metabolites, making outcomes unpredictable and raising toxicity risk.
What this interaction means in plain words
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Regorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Cobicistat inhibits CYP3A4 metabolism of regorafenib.
What to do
Avoid if possible and use an unboosted antiretroviral regimen. Otherwise monitor liver function and tolerability.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elvitegravir / cobicistat / emtricitabine / tenofovir df and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Frequently asked questions
Can I take Elvitegravir / cobicistat / emtricitabine / tenofovir df with Regorafenib?
MediHelp rates the interaction as major. Elvitegravir / cobicistat / emtricitabine / tenofovir df and Regorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Cobicistat is a strong CYP3A4 inhibitor and may increase regorafenib concentrations while reducing its active metabolites, making outcomes unpredictable and raising toxicity risk.
How serious is the interaction between Elvitegravir / cobicistat / emtricitabine / tenofovir df and Regorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible and use an unboosted antiretroviral regimen. Otherwise monitor liver function and tolerability.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
